Back to search

Ireland· IE-PA-EU/1/17/1252/001-002

Fasenra 30 mg solution for injection

A benralizumab product containing benralizumab, registered in Ireland by AstraZeneca AB. The same ATC class is registered in 16 of our 19 countries.

ATC R03DX10

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedFasenra 30 mg solution for injectionATCR03DX10REGISTER NO.IE-PA-EU/1/17/1252/00…PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Benralizumab is registered in 16 of 19 countries.

Countries holding a registration under ATC R03DX10 (benralizumab), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 10 of them publish a price we can compare per daily dose

Benralizumab · ATC R03DX10

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Benralizumab
Manufacturer
AstraZeneca AB
Country
Ireland (IE)
ATC code
R03DX10
ATC class
Benralizumab
Defined daily dose
0.54 mg, P
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/17/1252/001-002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Benralizumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All benralizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Fasenra
  • Liechtenstein · Fasenra
  • Norway · Fasenra

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/db0afa29-a03e-4505-8e90-c937ea728cae
GET /v1/drugs/db0afa29-a03e-4505-8e90-c937ea728cae?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled syringe",
  "routes": [
    "Subcutaneous use"
  ],
  "source": "hpra",
  "atc_all": [
    "R03DX",
    "R03DX10"
  ],
  "strength": null,
  "pa_number": "EU/1/17/1252/001-002",
  "substances": [
    "Benralizumab"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": null,
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about benralizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.